File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: An intranasal influenza virus-vectored vaccine system for blocking SARS-CoV-2 and influenza virus infection
| Title | An intranasal influenza virus-vectored vaccine system for blocking SARS-CoV-2 and influenza virus infection |
|---|---|
| Authors | |
| Issue Date | 16-Dec-2022 |
| Abstract | We have developed an intranasal vaccine candidate based on a live attenuated influenza virus (LAIV) with a deleted NS1 gene that encodes cell surface expression of the receptor-binding-domain (RBD) of the SARS-CoV-2 spike protein, designated DelNS1-RBD LAIV. Immune responses and protection against SARS-CoV-2 variants challenge following intranasal administration of DeINS1-RBD vaccines were analyzed in animal models and compared with intramuscular injection of the mRNA vaccine. Notably, vaccination with DeINS1-RBD4N-DAF LAlVs, but not mRNA vaccine, blocked replication of SARS-CoV-2 variants, including Delta and Omicron variants, in the respiratory tissues of animals. A phased III study found DelNS1-RBD LAIV is highly safe and effective in humans. More importantly, DelNS1-RBD LAIV retain the full ability to induce immunity against influenza viruses. The DeINS1-RBD LAIV system is an ideal technology for creating dual function vaccines against both influenza and COVlD-19 for use In annual vaccination strategies. |
| Persistent Identifier | http://hdl.handle.net/10722/337724 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chen, Honglin | - |
| dc.date.accessioned | 2024-03-11T10:23:23Z | - |
| dc.date.available | 2024-03-11T10:23:23Z | - |
| dc.date.issued | 2022-12-16 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/337724 | - |
| dc.description.abstract | <p>We have developed an intranasal vaccine candidate based on a live attenuated influenza virus (LAIV) with a deleted NS1 gene that encodes cell surface expression of the receptor-binding-domain (RBD) of the SARS-CoV-2 spike protein, designated DelNS1-RBD LAIV. Immune responses and protection against SARS-CoV-2 variants challenge following intranasal administration of DeINS1-RBD vaccines were analyzed in animal models and compared with intramuscular injection of the mRNA vaccine. Notably, vaccination with DeINS1-RBD4N-DAF LAlVs, but not mRNA vaccine, blocked replication of SARS-CoV-2 variants, including Delta and Omicron variants, in the respiratory tissues of animals. A phased III study found DelNS1-RBD LAIV is highly safe and effective in humans. More importantly, DelNS1-RBD LAIV retain the full ability to induce immunity against influenza viruses. The DeINS1-RBD LAIV system is an ideal technology for creating dual function vaccines against both influenza and COVlD-19 for use In annual vaccination strategies.</p> | - |
| dc.language | eng | - |
| dc.relation.ispartof | 2nd Symposium on Combating Emerging Infectious Diseases (16/12/2022-16/12/2022, Hong Kong) | - |
| dc.title | An intranasal influenza virus-vectored vaccine system for blocking SARS-CoV-2 and influenza virus infection | - |
| dc.type | Conference_Paper | - |